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Abstract
Over the past decade, metabolomics has emerged as an important technique for systems biology. Measuring all the metabolites in a biological
system provides an invaluable source of information to explore various cellular processes, and to investigate the impact of environmental
factors and genetic modifications. Nuclear magnetic resonance (NMR) spectroscopy is an important method routinely employed in metabolomics. NMR provides comprehensive structural and quantitative information useful for metabolomics fingerprinting, chemometric analysis,
metabolite identification and metabolic pathway construction. A successful metabolomics study relies on proper experimental protocols for
the collection, handling, processing and analysis of metabolomics data. Critically, these protocols should eliminate or avoid biologicallyirrelevant changes to the metabolome. We provide a comprehensive description of our NMR-based metabolomics procedures optimized for
the analysis of bacterial metabolomes. The technical details described within this manuscript should provide a useful guide to reliably apply
our NMR-based metabolomics methodology to systems biology studies.
Keywords: NMR; metabolomics; chemometrics; Mycobacterium; Staphylococcus; bacteria .

Abbreviations
NMR, Nuclear Magnetic Resonance; MS, Mass Spectrometry; LC, Liquid Chromatography; GC, Gas Chromatography; CE, Capillary
Electrophoresis; PCA, Principal Component Analysis; OPLS-DA, Orthogonal Projection to Latent Structures Discriminant Analysis; HSQC,
Heteronuclear Single Quantum Coherence; TOCSY, Total Correlated Spectroscopy; TCA, Tricarboxylic Acid; TSB, Tryptic Soy Broth;
MADC, Middlebrook Albumin Dextrose Catalase; CFU, Colony Forming Unit; MIC50, Minimum Inhibitory Concentration required to
inhibit the growth of 50% of organisms; SOGGY, Solvent Optimized Gradient-Gradient Spectroscopy; HSQC0, Time-Zero HSQC; TMSP-d4,
3-(trimethylsilyl)propionic acid-2,2,3,3-d4.

1. Introduction
Metabolomics is the study of small molecules in a biological system that participates in the metabolic reactions responsible for cell growth, survival, and other normal cellular
functions [1-3]. Additionally, the metabolome responds to
transcriptional and translational alterations associated with
genotypical, epigenetic, or environmental perturbations [47]. Thus, metabolomics provides an assessment of global
perturbations with respect to an altered genome, proteome,
or environment [2, 8, 9]. The simultaneous integration of

genomic, transcriptomic and proteomic data has enabled an
in-depth analysis of the interplay, interaction, and regulation
of DNA, RNA and proteins [10-12]. Along this line,
monitoring the bacterial metabolome and integrating the
results with other “omics” data has provided valuable
insights into bacterial adaptability [13], biofilms [14],
evolution [15], pathogenesis [16], and drug resistance [17].
Depending on the organism and growth state, the total
number of metabolites within a cell varies between several
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hundred to a few thousand, with a corresponding diversity
in physical and chemical properties, such as size, stability,
and concentration [18]. In addition to the challenge of the
simultaneous study of all the metabolites within a given
biological system [19], the selection of an analytical
technique will influence which metabolites are observed.
NMR and MS are commonly employed for metabolomics,
where both instruments can be interfaced with LC, GC, and
CE systems to select and emphasize specific components of
the metabolome [20-24]. NMR has a number of advantages
in analyzing the metabolome that includes minimal sample
handling and that it is not reliant on chromatography to
purify or separate metabolites. In addition, multiple
resonances from a single molecule increase the accuracy of
metabolite identification and quantitation. This accuracy can
be further enhanced by the application of 13C- and 15Nisotope labeling to enhance specific regions of the
metabolome [25, 26]. Importantly, the choice of 13C- or 15Nlabeled metabolite determines the region of the metabolome
observed by NMR, providing significant flexibility in
experimental design. In contrast to MS, NMR is a relatively
insensitive technique and only observes the most abundant
(≥ 1 to 5 μM) metabolites. In addition, MS has the advantage
of detecting a wider-range of the metabolome. However,
because of the relatively low molecular-weight range of the
metabolome,
MS
methods
generally
require
chromatography to separate metabolites before analysis [27].
Additionally, variations in ionization and the occurrence of
ion suppression in a complex mixture add uncertainty in
detecting specific metabolites by MS [28]. Finally,
quantitation by MS is typically more challenging than NMR.
Taken together, NMR and MS each have strengths and
weaknesses but should be viewed as complementary
techniques [29].
NMR-based metabolomics have been used to study a wide
range of biological systems such as tissues [30], biofluids
[31], mammalian cell cultures [32], plants [33] and bacteria
[34-36]. The overall procedure for an NMR-based
metabolomics study includes the following general steps: cell
growth and harvesting, metabolite extraction, NMR data
collection and analysis, multivariate statistical analysis,
metabolite identification and quantification [37]. Typically,
one-dimensional (1D) 1H NMR spectra are used for a
multivariate analysis such as principal component analysis
(PCA) or orthogonal projection to latent structures
discriminant analysis (OPLS-DA) [38, 39]. Both PCA and
OPLS-DA provide global profiles of metabolome changes
[40, 41]. Two-dimensional (2D) 1H,13C Heteronuclear Single
Quantum Coherence (HSQC) or 1H,1H TOtal Correlated
SpectroscopY (TOCSY) NMR experiments are used for the
quantitative assessment of metabolite changes resulting from
genetic modification or external stimuli [5, 14]. The ability to
generate global profiles and quantitative differences coupled
with the ease of applying NMR-based metabolomics has
contributed to the rapid growth of the NMR metabolomics
field. While NMR data acquisition and analysis methods are

improving, care must be taken to ensure that the methods
are appropriate to the task at hand and generate biologically
relevant information. As an example, protocols to efficiently
extract metabolites without inducing cellular changes are
essential for success [32, 42]. In brief, the observed changes
in the metabolome should reflect a change in the state of the
system instead of how the cells are handled and processed.
Similarly, variations in instrument performance, choice of
procedures for data collection and processing, and
invalidated models from multivariate analysis may induce
unintended biases or incorrect interpretation of
metabolomics data [43-46].
Since NMR-based metabolomics is a relatively new and
still developing technology, improving and enhancing the
experimental protocols is necessary to advance the field and
ensure continued success. Toward this end, we describe our
recently developed and optimized protocols for the
application of NMR metabolomics to microbial samples. We
present our current methodology and also discuss the
challenges associated with each major step of the process: (i)
sample preparation, (ii) NMR data collection and
processing, (iii) multivariate statistical analysis, (vi)
metabolite identification and network generation.
Specifically, the overall methodology will be discussed in
detail, where a number of key features will also be
highlighted, such as automation, bioinformatics,
experimental design, and harvesting the metabolome. The
focus of our efforts has been to identify and minimize
procedural steps that negatively influence the outcome of an
NMR-based metabolomics experiment.
2. Experimental Design
A general protocol for the analysis of bacterial metabolomes using NMR is shown in Figure 1. The flow diagram
illustrates procedures for both a global analysis of metabolome changes (metabolomics fingerprinting); and the identification and quantitation of specific metabolites correlated
with the biological process (metabolomics profiling). The
overall process consists of the following key steps: bacterial
cultivation and harvesting, metabolite extraction, NMR data
collection and analysis, multivariate statistical analysis, metabolite identification and quantification. Successful metabolomics sample preparation involves three steps. The first step
is the simultaneous growth of all of the bacterial cultures or
as many as is practical at a time. The bacteria are grown in a
standard medium for fingerprint analysis, whereas the medium is supplemented with a 13C-labeled metabolite for metabolomics profiling [47, 48]. After the bacteria are grown for a
defined time or they have achieved a specified cell density,
the second sample preparation step involves harvesting the
bacteria, quenching to halt all enzymatic processes, and
washing to remove the medium. The third sample preparation step involves lysing the cells and extracting the metabolome. A variety of solvents are routinely employed depending on the solubility of the targeted metabolites (cytosolic
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Figure 1. A flow chart of our protocol used for the NMR analysis of bacterial metabolomes.

metabolites, lipids, etc.). The metabolomics samples are then
used to generate a series of NMR spectra, which are used for
the multivariate statistical analysis, metabolite identification
and quantification. The individual steps of the NMR-based
metabolomics protocol will be discussed in detail highlighting challenges associated with each step.
2.1 Identify the appropriate biological system for a metabolomics study
NMR-based metabolomics is an important tool in systems
biology research. The quantitative and qualitative measure-

ment of metabolites from cytosolic extracts can be extremely
valuable for investigating cellular processes, pathogenesis,
and the effects of drugs or the environment on bacteria. Unfortunately, the bacterial metabolome is a complex mixture
of metabolites and numerous interconnected metabolic and
signaling pathways. This high interconnectivity may result in
significant metabolite concentration changes far from the
origin of the perturbation (inhibited, inactivated or downregulated protein). Correspondingly, it is easier to observe
changes to the metabolome than deduce the primary source
of the perturbation after its impact has rippled throughout
the metabolome. As an illustration, treating a bacterial cul-
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ture with a particular drug would be expected to lead to a
global change in the metabolome, but interpreting these
changes to identify the therapeutic target is extremely challenging. To address this challenge, the in vivo mechanism of
action of a potential drug lead may be determined by comparing these metabolome changes to other drugs with
known biological targets [49] or to a mutant bacteria where a
specific protein target is ablated or modified by genetic inactivation [50, 51]. This example illustrates that the comparative analysis between two or more metabolomes is an effective application of metabolomics. In order to obtain reliable
insights into the physiology of bacteria or any other organism, it is essential to identify and establish at least two reference metabolomes (wild-type vs. mutant, drug-resistant vs.
drug susceptible, nutrient-rich vs. nutrient-limited, etc.) for
a comparative analysis. Once the reference conditions are
established, bacteria can be exposed to any range of experimental variables such as a drug treatment, environmental
stimuli (pH, temperature, nutrient change), or gene knockout (mutants, RNAi, inhibitor) to determine if similarities
exist with the reference metabolome. The similarity between
metabolomes infers an overlap in the underlying physiological processes or responses that gave rise to the metabolome
changes. We have used this approach to demonstrate the
similarity of Staphylococcus epidermidis metabolomes resulting from exposure to divergent environmental stressors
that are known to facilitate biofilm formation [5, 14, 52].
Our results suggested that the tricarboxylic acid (TCA) cycle
acts as a metabolic signaling network to transduce external
stresses into internal metabolic signals. This conclusion was
only possible because the experimental design was based on
comparing the metabolomes of the S. epidermidis wild-type
strain 1457 and an aconitase mutant strain 1457-acnA::tetM
with and without the treatment of biofilm stressors. In
summary, the successful outcome of a metabolomics study
hinges on the experimental design and the proper choice of
the cellular metabolomes to be compared.
2.2 Minimize unintended bias and biologically irrelevant
variations
In addition to the proper choice of bacterial strains to
compare in a metabolomics study, the experimental
protocols must be optimized to reduce unwanted variation
or bias in the collection of cell-free lysates. It is essential to
ensure that any metabolome changes are limited to
biologically relevant factors and are not caused by the
handling or processing of the samples. Thus, the key to
metabolomics is establishing an efficient methodology that
closely captures the true state of the metabolome [53, 54].
Fundamental to a successful metabolomics experiment is
maximizing the uniformity of the preparation, handling,
processing, and analysis of each replicate sample [35, 45, 5558]. In instances where cultivation and/or processing
variation is unavoidable (e.g., if multiple incubators are
required to accommodate all the replicates), then the

cultures should be randomly distributed between the
incubators to minimize bias. Ideally, all of the metabolomics
samples should be handled by the same person because
subtle differences in individual techniques may influence the
outcome. If multiple investigators are required to efficiently
handle the samples, each researcher should be assigned a
specific set of tasks that are consistently applied to each
sample. For example, one investigator lyses all the bacterial
cells while another performs the metabolome extraction
procedure on every sample.
2.3 Optimization of the number of replicates to maximize
statistical significance
As with sample cultivation and preparation methods, the
NMR spectra generated from metabolomics samples need to
accurately represent the state of the system. In other words,
the NMR spectra must reflect the actual concentrations and
identity of the metabolites present in the biological sample at
the time of harvest. If the sample preparation and data
acquisition represent the metabolic status at the time of
harvest, then multivariate statistical techniques, such as PCA
and OPLS-DA, will enhance the identification of similarities
or differences in the NMR spectra, and, correspondingly,
between the bacterial metabolomes [39]. These multivariate
statistical techniques typically involve multiple replicates of
1D 1H NMR or 2D 1H,13C HSQC spectra for each bacterial
class or group (e.g., wild-type, mutant, drug treated, etc.).
The exact number of replicates is dependent on a number of
factors: (i) the variance within a group, (ii) the variance
between groups, (iii) the number of variables, and (iv) type
of statistical analysis performed [59, 60].
In most metabolomics experiments, the number of
biological samples is significantly smaller than the number of
variables; in this case, the variables correspond to peaks in
the NMR spectra or the detectable metabolites [60]. For this
reason, a larger number of replicates (≥ 6) per class are
required to obtain a statistically significant PCA or OPLSDA model. While greater numbers of replicates are
desirable, there are practical considerations to increasing the
number of replicates, including increased experimental time,
availability of incubator space, and practical limits on the
number of samples that can be simultaneously prepared and
processed within a reasonable time frame. The increased
time, larger number of samples, and added complexity may
be detrimental to maintaining consistency between samples,
where metabolite stability may become more of an issue
[61]. So the potential benefit in improving the reliability of
the PCA or OPLS-DA models may be negated by too large of
a sample size if sample consistency is sacrificed. In general, 6
to 10 replicates per class can be routinely handled while
providing a statistically significant PCA or OPLS-DA model.
Lastly, to increase the sample consistency, the application of
an automated sample changer or flow-probe can minimize
variability by eliminating human involvement and providing
a uniform and consistent protocol for NMR data collection.
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3. Sample Preparation
3.1 Techniques for consistent bacterial cultivation
Consistency is critical to metabolomics, where variations
in a bacterial metabolome may be introduced by cultivation
protocols. To achieve the reproducible cultivation of bacteria
requires consideration of three variables: bacterial strain,
culture medium, and cultivation conditions. Strain selection
is often driven by investigator preference, availability, or
cultivability. The choice of culture medium will largely depend on which, if any, isotopically-labeled metabolite is being followed. For example, when using 15N-arginine, it is
impractical to add labeled arginine to a complex medium
containing an unknown concentration of unlabeled arginine.
In this example, to achieve maximal labeling of the bacteria,
it would be best to use a chemically defined medium lacking
arginine. Importantly, the culture medium has to be consistently employed throughout a specific metabolomics study of
a defined set of bacterial strains. A different culture medium
cannot be used for metabolomics fingerprinting and profiling, it cannot vary based on the requirements of the bacterial
strain or to accommodate an experimental variable. For example, if a mutant bacterial strain requires the addition of a
supplement for viability, then it is also necessary to add the
same amount of the supplement to all other bacterial cultures in the study. Simply, any difference in the composition
of the culture media will induce changes in the metabolome
that will mask or complicate any analysis. Of course, the
culture medium needs to be optimized for the specific requirements of each species and bacterial strain and, correspondingly, will likely vary between metabolomic studies. A
metabolomics study employing Staphylococcus epidermidis
will use a different culture medium than a study involving
Mycobacterium smegmatis.
Bacterial cultures also need to be properly handled in order to avoid inducing biologically irrelevant changes. For
example, pre-warming the culture medium prevents temperature shock and minimizes variation between biological replicates. Similarly, randomizing the samples from each group
and class also minimizes bias that may occur if all the samples are processed in a predefined order. Importantly, different cell types may require special care or different handling
protocols. Cultivation conditions will also vary depending
upon the experiment; however, consideration must be given
to each of the following: temperature, pH buffering (if used),
% CO2 (if used), the flask-to-medium ratio, the revolutions
per minute of agitation (if used), the use of baffled or nonbaffled flasks, and the inoculum dose. In effect, one protocol
does not necessarily “fit all” and a general metabolomics
protocol needs to be optimized for each experiment and cell
type.

step in the design of a metabolomics study. The volume of
the bacterial culture should be large enough to provide a
sufficient number of cells to maximize the NMR signal-tonoise, but small enough to simplify the handling of numerous replicate samples. An appropriate cell density must be
determined empirically for each species and bacterial strain,
which will also limit the culture size. Similarly, the growth
phase chosen for harvesting bacteria will also contribute to
defining the optimal culture size since cell density changes
drastically between the lag, exponential and stationary phases. In our experience with staphylococcal and mycobacteria
cultures, media volumes between 15 to 50 mL are used to
grow cells to an optical density at 600 nm (O.D.600nm) of 1-2
for bacterial cultures collected during the exponential phase.
Conversely, media volumes of between 3 to 5 mL are used to
grow cells to an O.D.600nm of 3 to 7 for bacterial cultures collected during the stationary phase (e.g., 6 to 7 for Staphylococcus epidermidis, and 3 to 4 for Mycobacterium smegmatis).
The overall goal is to have an O.D.600nm of 10 to 20 after the
bacterial cells have been concentrated to a final volume of 1
ml. This will ensure metabolite concentrations sufficient for
detection by NMR. These culture volumes and O.D.600nm values should be viewed as guidelines and targeted goals that
may require further optimization for different bacterial
strains or species.
Ideally, each bacterial culture should contain the same
number of cells and be at the same growth phase when harvested. In reality, differences in cultivation conditions, media, and/or bacterial strains may substantially affect growth
rates and/or growth yields. The two more common approaches to compensate for different bacterial growth rates
are: collect the bacteria when they have reached the same cell
density, but at different times to account for the different
growth rates; and harvest the bacteria at the same time but
harvest equivalent cell numbers. The number of bacterial
cells in a given culture is estimated by measuring the culture
turbidity using a standard optical density method. As examples, in staphylococci, the exponential and stationary growth
phases were typically analyzed at the 2 h and 6 h time points,
respectively [5]. For our mycobacterial experiments, a consistent growth phase was achieved by harvesting bacteria at a
uniform O.D.600nm of 1.2. In practice, it is extremely difficult
to harvest every bacterial culture with an identical O.D.600nm
value. To correct for this variability, all the bacterial cultures
are normalized to the same O.D.600nm value. Simply, the cultures are suspended into a phosphate buffer until the
O.D.600nm values are equal. Alternatively, the bacterial cell
cultures can be normalized based on colony-forming units
(CFU), if OD-CFU calibration curves are available, or total
protein concentration.
3.3 Sample preparation protocols to maximize isotope labeling
efficiency

3.2 Sample optimization to maximize NMR sensitivity
Identifying an optimal culture size is an important next

Metabolomics profiling requires 13C- or 15N-labeled metabolites and defines the choice of culture media. In our la-
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boratories, we typically label staphylococci using 13C-glucose
in the complex medium tryptic soy broth (TSB) that is devoid of unlabeled glucose [6, 7]. This medium allows for
maximal biomass generation, while assuring that nearly all
(~99%; 1.1% is due to naturally occurring 13C) of the 13Clabeled metabolites in the metabolome were derived from
glucose. Similarly, we have labeled mycobacteria using 13Cglucose or 13C-glycerol in Middlebrook 7H9 Albumin Dextrose Complex (MADC; Becton-Dickinson) media. We have
also supplemented culture media with 13C-alanine, 13Caspartate, 13C-glutamate, 13C-proline and 13C-pyruvate as a
more targeted approach to the analysis of the metabolome.
These metabolites are associated with a limited number of
metabolic pathways. The analysis of the metabolome can be
further focused by using a targeted metabolite where only
one or a few specific carbons in the metabolite are 13C labeled. Only the metabolic pathways involving the specific 13C
-labeled carbon will be observable by NMR. The concentration of the 15N-, or 13C-labeled metabolite needs to be high
enough (≥ 1 to 5 μM) to be detected by NMR. In our experience with staphylococcal and mycobacterial cultures, the
volumes range from 25 mL to 100 mL and the culture media
should be supplemented with approximately 2.5 to 4 g/L of
13C -glucose or ~10-15 mg/L of a targeted metabolite like 13C
6
-D-alanine in order to acquire a 2D 1H-13C HSQC spectrum
with acceptable signal-to-noise.
3.4 Protocols for determining an optimal drug dosage or administering other stress treatments
To ensure consistency, the experimental variable such as a
drug treatment, environmental stimuli, or gene knockout
needs to be uniformly applied to the “treatment” class. An
additional consideration for treatment of cultures, is that the
impact on the metabolome should be strong enough to detect [49]. In other words, a particular drug dosage needs to
be large enough to affect the cellular metabolome relative to
untreated cells, but should not induce cell death. In our experience, a drug concentration that inhibits bacterial growth
by 50% relative to untreated cultures is a desirable target [49,
50]. The availability from the literature of a minimal inhibitory concentration for the strain (MIC), or otherwise for the
population isolates (MIC50), provides a good starting point
for optimizing a drug dosage, but the actual dosage must be
determined empirically for each set of cultivation conditions.
In our experience, literature MIC or MIC50 values tend to be
too low for cultivation conditions used for metabolomics.
We typically test drug concentration ranges at between 1 to
24 times the reported MIC or MIC50 values in order to identify an optimal drug dosage. Importantly, this also implies
that drugs with a range of biological activity will require
different drug concentrations in a metabolomics study;
hence, the use of the 50% inhibition of growth is used as a
metric as opposed to drug concentration. Typically, in our
experiments the drug treatments are normally administered
during the exponential phase and the bacteria are allowed to

grow for at least one generation before harvesting. In our
experience, this provides a sufficient amount of time for the
drug to affect cell physiology and induce a perturbation in
the metabolome. Administering a drug at an earlier time
point can be problematic because of the inability to harvest
enough bacteria.
3.5 Quenching, washing and harvesting the bacterial cells
Speed is critical to harvesting bacteria without inducing a
change to the metabolome. Changes occur quickly because
of different metabolite turnover-rates, varying stabilities, and
the induction of stress responses, among other factors [6163]. As bacteria are being harvested, the environment is
changing dramatically: (i) the bacteria are either adhered to
the surface of filter paper or at the bottom of a centrifuge
tube under anaerobic conditions, (ii) the temperature is
changed from 37oC to ~ 0oC, and (iii) the growth media is
replaced with a phosphate buffer. To prevent perturbations
to the metabolome caused by handling of the cell samples,
the bacteria need to be rapidly quenched in order to stop all
cellular processes from responding to these changes.
Quenching efficiency has been widely discussed in the
literature [42, 64-66]. Importantly, the quenching technique
employed also defines the washing protocol and the order
that quenching, washing and cell separation takes place. Our
quenching techniques consist of filtered cells being quickly
submerged into liquid nitrogen or the cells and media being
directly added to -60oC cold ethanol or methanol solution
while being vortexed. The media and ethanol/methanol
volumes are at an equal 1:1 ratio. After centrifugation, the
supernatant is decanted and disposed of, and the cell pellet is
ready for washing. Unfortunately, there is a possibility of cell
leakage and loss of metabolites when the cells are directly
added to the cold ethanol or methanol solution.
Before intracellular metabolites can be analyzed, the
bacteria need to be rapidly separated from the culture media.
Filtration and centrifugation are both routinely used in our
laboratory to separate bacterial cells from the media.
Filtration has a definitive advantage because it is significantly
faster than centrifugation, but challenges in removing and
collecting intact cells from filter paper may lead to sample
variability. Conversely, the variability between metabolome
replicates is expected to be reduced with centrifugation
because of the ease in handling the cells. Nevertheless, our
experience with washing bacterial cells using either filtration
or centrifugation has resulted in essentially identical
metabolomics fingerprints (Figure 2a); thus, any undesirable
variation within a group likely occurs during sample
preparation.
The use of centrifugation or filtration also determines the
quenching protocol [36]. Harvesting bacteria using
centrifugation requires quenching the bacteria using the
direct addition to -60oC cold ethanol or methanol. The
bacteria, culture media, and quenching solution are in a
properly sized conical centrifuge tube that is centrifuged for
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Figure 2. Illustrations of the impact of (a) filtration and centrifugation, (b) number of extraction steps, (c) type of wash buffer, and (d)
lyophilization on the composition of the metabolome.

8 minutes at 4,284 g (bucket rotor) and ≤ 4oC. Following
centrifugation, the culture media and quenching solution are
decanted and the bacteria are suspended in 30 mL of an ice
cold wash. We routinely wash bacteria with either a
phosphate buffer (20 mM, pH 7.2), or phosphate buffered
saline (PBS; 6 mM phosphate buffer, pH 7.4, 137 mM NaCl
and 2.7 mM KCl) to remove residual media and avoid
contamination of the metabolome. The buffered wash
eliminates any impact on the cells from a pH or osmotic
change that may lead to cell leakage and loss of metabolites.
The bacteria are centrifuged again, the wash is decanted off
and the process is repeated. After two washes, the cell pellet
is suspended in 1 mL of the ice cold wash and transferred to
a 2 mL vial for cell lysing. Additional washings provide an
insignificant benefit in removing media contaminates, but
results in an undesirable increase in time. The cells are kept
on ice throughout this entire process.
Harvesting bacteria by vacuum filtration collects the
bacteria on sterile filter paper (0.45 μm pore size; Millipore),
while simultaneously removing the media. The number of

bacteria that can be harvested onto a filter must be
empirically determined to prevent a filter blockage. Under
proper conditions, removing the media should take less than
a minute, and should never exceed two minutes. If this
cannot be achieved, then the bacteria need to be harvested
using centrifugation. After filtration, the filter paper
containing the cells is then quickly placed into a 50 mL
conical centrifuge tube and submerged into liquid nitrogen
to freeze and quench the cells. The conical vial is then
warmed by placing it into a bucket of ice for ~1 to 2 minutes.
This prevents freezing of the 1 mL of wash that is added to
the conical vial. The cells are gently removed from the filter
paper with the wash and then transferred to a 1.5 mL
microcentrifuge tube. The cells are centrifuged and washed
once (1 mL).
3.6 Cell lysing and metabolite extraction
The cells need to be lysed in order to extract the cellular
metabolome. Cells can be lysed by chemical or physical
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means, but the use of chemicals runs the added risk of
contaminating the metabolome. Thus, the FAST-Prep bead
beating method of lysing cells is our preferred approach.
Each sample is placed into a 2 mL micro-centrifuge tube
with small glass beads (Lysing Matrix B; MP Biomedical)
and 1 mL of extraction buffer. The cells are crushed by bead
beating for 40 to 60 seconds in the FAST-Prep instrument at
a speed of 6.0 m/s. This process is repeated after keeping the
crushed cells on ice for 5 minutes. The sample is then
centrifuged for 2 minutes at 17,000 g to pellet the cell debris.
The supernatant with the extracted metabolites is collected.
The cell debris is washed 1 to 3 times with 1 mL of the
extraction buffer to maximize the metabolome yield (Figure
2b). Also, double distilled water or a phosphate buffer are
routinely used as the extraction buffer, since both
approaches provide similar results (Figure 2c). All extracts
per sample are combined for lyophilization, where the
sample is then dissolved in 700 μL of a phosphate buffer in
D2O at pH 7.2 (uncorrected). Lyophilization may negatively
impact some volatile metabolites, but, in general, no effect is
observed (Figure 2d). A major concern during the extraction
step is maximizing the overall yield while minimizing any
perturbation to the metabolome. In our experience, the cell
lysing and metabolite extraction process will require
approximately 45 minutes for 30 cultures. The metabolomics
samples can be stored in a -80oC freezer or directly
lyophilized over-night.
4. NMR Spectroscopy
4.1 One-dimensional 1H NMR methodology
One-dimensional (1D) 1H (proton) NMR is an unbiased,
nonselective, and nondestructive approach that requires no
modification of the samples, where the data can be collected
in a high-throughput manner. A 1D 1H NMR spectrum contains numerous proton signals generated from a complex
metabolomics mixture, where the chemical shift of each signal describes the structural characteristic of a specific metabolite. Moreover, the peak intensities or volumes are directly
proportional to the concentration of each metabolite. Quantification of metabolites can be achieved by using an internal
standard with a known concentration, where we routinely
use 50 μM 3-(trimethylsilyl) propionic acid-2,2,3,3-d4
(TMSP-d4, Sigma). Thus, 1D 1H NMR experiments combined with multivariate statistics are commonly used for the
global analysis of the metabolome.
Collecting 1D 1H NMR data for metabolomics is fast and
simple, and provides highly reproducible and accurate results. Importantly, the NMR experimental parameters need
to be identical for each metabolomics sample in order to
collect reliable metabolomics data. Any per sample variation
will erroneously bias the resulting clustering patterns in the
PCA and OPLS-DA scores plot. To avoid this and maintain
sample consistency, we use a BACS-120 sample changer,
Bruker ICON-NMR, an automatic tuning and matching

(ATM) unit, and autoshim to automate the NMR data collection. Nevertheless, instrument drift may still occur during
the high-throughput metabolomics screen, so it is also important to randomize the samples during NMR data collection. If an NMR spectrum is collected first for all the control
samples followed subsequently by each treatment class, there
is a significant potential of inducing a biologically irrelevant
bias into the analysis. The clustering pattern in the PCA and
OPLS-DA scores plot may be dominated by the order of data
collection instead of the expected biological differences.
In our laboratory, a typical 1D 1H NMR spectrum is collected using 128 scans and 32k data points on a Bruker 500
MHz Avance DRX NMR spectrometer equipped with a triple-resonance, Z-axis gradient cryoprobe. The acquisition
time is approximately 10 minutes per sample. The goal is to
obtain optimal signal to noise while minimizing the total
experimental time. We previously demonstrated that spectral noise is detrimental to the resulting PCA and OPLS-DA
scores plot [55]. Random noise fluctuations results in large
and irrelevant variations in the scores clustering. To avoid
this problem, spectral noise needs to be removed prior to
PCA and OPLS-DA. Correspondingly, the quality of the
within class clustering in PCA and OPLS-DA scores plot is
directly dependent on the spectral signal-to-noise (Figure 3).
The within class variance decreases dramatically as the
number of scans (signal-to-noise) is increased from right to
left in the scores plot. Importantly, the spectral noise was still
removed prior to PCA. Thus, the accuracy of identifying
similarities or differences between multiple classes is
dramatically improved by reducing within class variance,
which is achieved by improving spectral sensitivity. Also,
correctly identifying class differences improves with the
number of replicates (Figure 4). The statistical significance of
cluster separation as measured by p-value [67] is shown to
decrease as both a function of group variance and the
number of replicates. As a result, we prefer to use ten
replicates per class and strive to achieve an average signal-tonoise ratio of > 100 to 200. This is achieved by simply
increasing the number of scans or the number of cells,
whichever is more practical. While signal-to-noise has a
dramatic impact on scores clustering, PCA and OPLS-DA is
indifferent to changes in spectral resolution unless the
number of data points is ≤ 2K.
A D2O phosphate buffer is the typical solvent of choice for
aqueous metabolomics samples in order to efficiently
remove residual water signals and avoid interference from
buffer signals. Water and buffer signals are problematic since
they can distort the NMR spectrum and may overlap and
obscure important metabolite signals. Most NMR processing
software can automatically remove the residual water peak,
but extra data processing is required to correct for baseline
distortions induced by the solvent. Unfortunately, simply
applying a baseline correction changes the PCA and OPLSDA clustering patterns [68]. Furthermore, different baseline
correction protocols will induce variable changes into the
scores plot. Also, removing the residual water peak may
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Figure 3. Illustration of the impact of the NMR signal-to-noise on within class variation in a PCA scores plot. From right to left, the 1D 1H
NMR spectra were collected with an increasing number of scans (1, 2, 4, 8, 16, and 32) resulting in a proportional increase in signal-to-noise.
All other experimental parameters were kept constant.

result in a potential loss of information by also removing
metabolite peaks near the water signal. Instead, a water
suppression technique that experimentally removes the
water peak without inducing baseline distortions is the
preferred alternative.
There are a variety of NMR pulse sequences for water

suppression that are available to the metabolomics
community, such as WATERGATE, water pre-saturation,
WET, and PURGE [69-73]. Our preferred choice for a water
suppression pulse sequence is Solvent-Optimized GradientGradient Spectroscopy (SOGGY). SOGGY does an
outstanding job in eliminating the water signal without

Figure 4. Illustration of the impact of within group variation and the number of replicates on the p values calculated between clusters in
a simulated PCA scores plot. From top to bottom, p values from the simulated PCA scores plot were calculated with an increasing number of
replicates (6, 8, 10) resulting in a proportional decrease in p values. Similarly, increasing the group variation by increasing the standard deviation (σ) per cluster resulted in a significant increase in p values.
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inducing any base line distortions (Figure 2) [73]. SOGGY is
a variant of excitation sculpting that employs a pulsed field
gradient with a simple phase-alternating composite pulse.
SOGGY offers the flexibility to optimize the 180 degree hard
pulse to achieve optimal excitation of the water signal, and
adjusting the 180 degree soft pulse to optimize the range of
the water frequency to be suppressed [73, 74]. As a result,
SOGGY efficiently suppresses the water signal while
removing any phase cycle artifacts. A flat baseline is obtained
while also maintaining metabolite signals near the water
signal [73]. SOGGY completely eliminates the need to apply
any baseline correction.

HSQC3) with an increased number of pulse sequence
repetitions. A natural log plot of peak areas or intensities
versus the increment number (1, 2, 3) allows for an
extrapolation back to increment 0 or zero-time. The
experimental parameters used in the HSQC0 experiment is
similar to the conventional method, but with some minor
variations. The number of scans is increased to 128 due to
the decrease in signal-to-noise in HSQC2 and HSQC3. To
partially compensate for the increase in experimental time,
the number of data points in the indirect dimension is reduced to 64. In general, the HSQC0 set of experiment requires approximately 6 hours per sample on our system.

4.2 Two-dimensional 1H-13C HSQC NMR methodology

5. Data analysis

The severe overlap of signals in a 1D 1H NMR spectrum is
a challenge for metabolite identification. The difficulty arises
because hundreds to thousands of peaks occupy a small
chemical shift range (~10 ppm), where multiple metabolites
share similar chemical shifts. Thus, we typically do not use
1D 1H NMR spectra to assign metabolites. Instead, we
routinely use 2D 1H-13C HSQC experiments for metabolite
assignments. The 2D 1H-13C HSQC experiment is a more
reliable approach for metabolite identification because of the
significantly higher resolution and the correlation between
1H and 13C chemical shifts for each C-H pair in a molecule
[75, 76]. Also, the 2D 1H-13C HSQC experiment simplifies
the analysis of the metabolome because only compounds
containing a 13C-carbon derived from the 13C-labeled
metabolite added to the media will be detected.
In our laboratory, we use a standard Bruker 2D 1H-13C
HSQC pulse sequence on our 500 MHz spectrometer, where
an acceptable signal-to-noise is achievable using 64 scans.
Similarly, a reasonable digital resolution is achieved by
collecting 2K and 128 data points in the direct and indirect
direction, respectively, with a corresponding spectral width
of 10 ppm and 140 ppm along the 1H and 13C axis,
respectively. Since some aromatic C-H pairs have a 13C
chemical shift greater than 140 ppm, the spectrum will
contain folded peaks, but the folded peaks will not interfere
with or overlap with other metabolite peaks due to their
unique position along the 1H axis (~ 7.0 ppm). This folding
technique allows for an increase in the digital resolution
without incurring an increase in acquisition time. In general,
the 2D 1H-13C HSQC experiment requires approximately 4
hours per sample on our system.
A conventional 2D 1H-13C HSQC spectrum is useful for
detecting metabolite changes by overlaying multiple spectra
to identify missing peaks or peaks with significant intensity
changes. Unlike 1D 1H NMR spectra, obtaining metabolite
concentrations is more difficult because peak intensities are
dependent on J-couplings, dynamics and relaxation, in
addition to metabolite concentrations [77, 78]. To quantify
absolute metabolite concentrations, we use the Time-Zero
HSQC (HSQC0) experiment [77]. This approach requires
collecting a series of three HSQCs spectra (HSQC1, HSQC2,

5.1 Preprocessing of 1D 1H NMR data
The 1D 1H NMR spectra are minimally processed (Fourier
transformed and phase corrected) using ACD/1D NMR
Manager (Advanced Chemistry Development). Each NMR
metabolomics sample contains 50 μM of TMSP-d4 as an internal standard, where each NMR spectrum is referenced to
the TMSP-d4 peak and uniformly aligned to 0.00 ppm. Also,
all peak heights are normalized to the intensity of the TMSPd4 peak. Intelligent bucketing within the ACD/1D NMR
Manager is then used to integrate each spectral region with a
bin size of 0.025 ppm. The spectra are normalized; noise regions and residual solvent and buffer resonances are removed, and then the remaining bins are scaled prior to PCA
and OPLS-DA using the commercial SIMCA12.0+
(UMETRICS)
statistical
package
(http://
www.umetrics.com/).
The need for data normalization and scaling prior to multivariate statistical analysis has been extensively discussed in
the literature [79, 80]. Normalization adjusts for
experimental variations between replicates, different number
of cells, varying signal-to-noise, etc., and minimizes these
contributions to the clustering patterns in PCA and OPLSDA scores plot. We have encountered significant success in
using a Z-score or center averaging the spectrum:
(1)

where X is the average signal intensity in a given spectrum,
σ is the standard deviation in the signal intensity, and Xi is
the signal intensity within bin i (Figure 5a). After normalization, all the noise bins are uniformly removed. This was initially accomplished by manually identifying a “reference”
noise region above 10 ppm and below 0 ppm; and calculating an average noise value. If a bin across all replicates had
an integral value of less than twice the average noise, it was
also identified as noise and removed (Figure 5b). The protocol for identifying noise regions has been recently improved
upon and results in smaller within class variations (Figure
5c). This also results in an improved separation between truly distinct classes and removed erroneous separations. For
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Figure 5. Illustration of the impact of NMR preprocessing on within and between class variations in a PCA scores plot. (a) The 1D 1H
NMR spectra was not properly preprocessed. The spectra were not normalized and the noise was not removed. The spectra were only Fourier
transformed, phased corrected, and the residual H2O resonance was removed. (b) The 1D 1H NMR spectra were processed as in (a) with the
addition of normalization using center averaging, but without noise removal. (c) The 1D 1H NMR spectra were processed as in (b) with the
addition of noise removal. Each spectrum was binned using intelligent bucketing with a bin size of 0.025 ppm. The ellipses correspond to the
95% confidence limits from a normal distribution for each cluster. The PCA scores plots compare the metabolomes of S. aureus wild-type
(wt) strain SA564 with an aconitase mutant (acna) strain SA564-acnA::tetM at either two hours (2h) or six hours (6h) of cell growth. Below
each PCA scores plot is a corresponding dendrogram generated from the scores using Mahalanobis distances, with p values for the null hypothesis reported at each branch.

example, the statistical significance between clusters 6hwt
and 6hacna improved from a p-value of 3.1x10-13 to 8.1x10-15,
while the small, but biologically irrelevant, separation between clusters 2hwt and 2hacna (p-value 2.5x10-3) was removed (Figure 5). Instead of using an average minimal signal intensity to define noise, we now define noise based on a
relative standard deviation. This is based on the expectation
that real NMR peaks from metabolites will have a higher
intrinsic variability compared to the noise because of biological variations that naturally occur even between within class
replicates. Conversely, the variability of the noise should be
effectively constant for a given spectrometer operating within normal parameters. Simply, the standard deviation and
average is calculated for each bin, where the standard deviation is normalized by the average peak intensity. This avoids
eliminating weak peaks with a relatively small standard deviation. The same is done for the reference noise region, which
is then used to define noise:
Noise:
Cutoff:

σi’≤σ0’
σ0’=avg(σn’)+2*sd(σn’)

(2)
(3)

where σi’,σn’ are the relative standard deviations (absolute
standard deviation divided by the mean) for the ith bin in
the spectral region and nth bin in the reference noise region,
respectively, and avg(σn’) and sd(σn’) are the mean and
standard deviation of σn’ respectively. In effect, any peak that
falls within the normal distribution of the reference noise
region is defined as a noise bin. This approach is better at
defining noise peaks in crowded and overlapping regions of
the NMR spectra.

In addition to normalization, each bin or column in the
data matrix also needs to be scaled to account for the large
dynamic range in peak intensities. PCA and OPLS-DA emphasizes the absolute variation in bins between classes. Correspondingly, the relative variation of an intense peak may
be insignificant compared to a weak peak, but the absolute
changes in its intensity may completely mask biologically
relevant changes in a small peak. Scaling increases the weight
of the low intensity peaks so strong peaks do not dominate
in PCA and OPLS-DA [79, 80]. In our experience, unit
variance scaling, also known as autoscaling or a Z-score (see
eqn. 1), has been shown to be effective in generating reliable
clusters with the correct separation based on biologically
relevant class distinctions. Also, within class variance is
reduced using autoscaling, which is our default scaling
method.
5.2 Multivariate statistical analysis of 1D 1H NMR data
We routinely apply PCA, a non-supervised technique, to
determine if the 1D 1H NMR data can easily distinguish
between the various test classes. PCA provides an unbiased
view of group clustering in the resulting 2D scores plot. We
only use a three-dimensional (3D) scores plot if class
separation in a 2D scores plot is insufficient and the PC3
contribution is significant (> 5 to 10%). OPLS-DA is only
used if class separation is observed in the PCA scores plot.
OPLS-DA is a supervised technique and assesses a
relationship between the NMR data class designations. We
limit OPLS-DA to only two class designations that
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differentiate between the single control group (0) and the
entire treatment group (1). As a supervised technique, OPLS
-DA maximizes a separation between these two classified
groups, while minimizing within class variations [39]. Thus,
OPLS-DA identifies the important spectral features
(metabolites) that primarily contribute to class separation.
We routinely use an OPLS-DA S-plot or loading plot (Figure
1) to readily identify the key metabolites that contribute to
class separation. Since OPLS-DA is a supervised technique
and can generate a class separation even for random data
[81], it is essential to verify the model [46]. But this is also an
advantage of OPLS-DA over PCA; the statistical significance
of the model is quantified. We cross-validate OPLS-DA
models using a modified leave-one-out method [82, 83] and
CV-ANOVA [84]. The modified leave-one-out method
provides a quality assessment score (Q2) and R2 values,
where CV-ANOVA provides a standard p-value. The
theoretical maximum for Q2 is 1, where a value of ≥ 0.4 is an
empirically acceptable value for biological samples [85], but
Q2 does not have a critical value for inferring significance. It
is still possible for an invalid model to produce a large Q2
value. Similarly, the R2 values only provide a measure of the
fit of the data to the model. But large differences between Q2
and R2 (R2 >> Q2) does suggest an over-fit model.
Conversely, a p-value << 0.05 from CV-ANOVA provides
clear validation of the OPLS-DA model.
In addition to validating the OPLS-DA model, it is also
extremely important to verify the statistical significance of
the clustering patterns in the PCA and OPLS-DA scores plot.
Is the between group difference larger than the within group
variations? One key factor is the number of replicate
samples. We have previously shown that increasing the
number of replicates improves the statistical significance of
cluster separation [86]. This finding is also supported by the
increase in p-values seen with an increase in within class
variations (Figure 4). Again, increasing the number of
replicates improves the statistical significance of the class
separation (lower p-value) even when within class variation
increases. Correspondingly, we routinely use 10 replicates
per group in our metabolomics study to improve the
likelihood of observing statistical significant class
separations.
It is also important to visually define each group or class
within the PCA and OPLS-DA scores plot and to classify the
statistical significance of the class separation. We developed
a free PCA and OPLS-DA utilities software package (http://
bionmr.unl.edu/pca-utils.php) [67] that draws ellipses or
ellipsoids around each group cluster in a scores plot, where
the ellipse corresponds to the 95% confidence limits from a
normal distribution for each cluster. Visual separation of the
ellipses infers a class separation. The same software package
is also used to generate a metabolomics tree diagram based
on the group clusters in the scores plot [67, 86]. Simply, a
centroid from each cluster is used to calculate a Mahalanobis
distance between clusters, where dendrograms are then
generated from the resulting distance matrix. The

significance of each node (cluster separation) is determined
by using standard bootstrapping techniques and returning a
bootstrap number [87], where a value above 50 infers a
significant separation; or from Hotelling’s T2 and Fdistributions that returns a p-value, where a number << 0.05
infers a statistically significant separation.
Observing a statistically significant difference in the global
metabolome between two or more bacterial samples is
typically the first objective of a metabolomics investigation.
While this difference may infer some biological significance,
the ultimate goal is to identify the underlying metabolites
and associated pathways that are the primary contributors to
the observed class separation in the PCA and OPLS-DA
scores plot. One approach is to generate an S-plot (Figure 1)
from the resulting OPLS-DA analysis. The S-plot identifies
the key bins or 1H chemical shifts that are correlated or anticorrelated with the separation between the two classes in an
OPLS-DA scores plot. The 1H chemical shifts can then be
compared against a number of online NMR metabolomics
databases [88-92] to assign the metabolites. Unfortunately,
an unambiguous assignment is rarely possible because of the
low chemical shift dispersion and the large number of
potential metabolites. Instead, 2D NMR experiments
combined with the biological knowledge of the system under
investigation are required to improve the accuracy of
metabolite identification.
5.3 Metabolite Identification
5.3.1 Automated peak picking of 2D NMR data
2D 1H,13C HSQC and 1H,1H TOCSY spectra are
commonly used for metabolite identification because of the
increase in chemical shift resolution achieved by spreading
the information out into two-dimensions. Also, the
correlation between 1H chemical shifts for each J-coupled H
pair; and the correlation between 1H and 13C chemical shifts
for each C-H pair significantly reduces the assignment
ambiguity. This occurs because both chemical shifts have to
match a single metabolite in the database to make an
assignment. Despite the advantages, peak picking and
organizing a table of intensities from a 2D NMR experiment
is a time consuming process, especially when multiple
spectra are involved. Numerous software packages are
available to automate the peak picking of 2D NMR spectra,
however; it is extremely difficult, if not impossible, to align
and match multiple sets of spectra with different peak
patterns due to unique metabolomes.
For example, three different sets of cell cultures (different
cell types, treatments or environmental conditions, etc.) will
each exhibit a distinct set of peaks in the NMR spectrum due
to the presence of unique metabolites. These unique peaks
will be mixed with other peaks common to all three groups,
but the relative peak intensities are likely to vary due to
different metabolite concentrations. Thus, if the control
group is designated as the reference spectrum for automated
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peak picking, a peak list will be generated that only contains
peaks observed in the control spectrum that are above the
designated noise threshold. Correspondingly, peaks unique
to the other two groups will be missed when this peak list is
used to peak pick their spectrum. In addition, weak peaks
may also be missed due to different noise levels between the
spectra and a corresponding difference in the threshold
setting for peak picking. Instead, a composite reference
spectrum for automated peak picking needs to be generated
that captures all the peaks present in the three separate
groups. We accomplish this task by using the addNMR
function in the free NMRpipe software package (http://
spin.niddk.nih.gov/NMRPipe/) [93]. As the name implies,
addNMR mathematically sums all spectra together from the
three groups to make a single spectrum. This resulting
“master spectrum” contains all the peaks observed
throughout the set of 2D experiments and is used to generate
a peak list for automated peak picking of each individual
spectrum. Critically, the 2D NMR spectra need to be
collected and processed using identical experimental

parameters (spectral width, data points, zero-filling, etc.) and
needs to be aligned to an internal reference (TMSP-d4). In
our experience, all the peaks from the complete set of NMR
spectra are routinely matched to the reference list by using a
chemical shift error-tolerance of 0.04 ppm and 0.25 ppm in
the 1H and 13C dimensions, respectively. This approach has
greatly simplified and increased the efficiency of a previously
laborious procedure. The addNMR command can also be
used to generate a difference spectrum that clearly highlights
the major spectral changes between two classes (Figure 6).
5.3.2 Assignment of an NMR peak to a metabolite
Metabolite identification is an extremely important
component of the metabolomics process because it enables
the determination of the key metabolites perturbed by the
treatment or the metabolites primarily contributing to class
distinction. This includes the discovery of important
biomarkers associated with drug efficacy or drug resistance.
Also, metabolite identification is important to the drug

Figure 6. (a-c) Illustration of the procedure to generate a “master spectrum” and facilitate automated peak picking by creating a complete
peak list. (a-b) Representative 2D 1H-13C HSQC spectra obtained from two distinct bacterial cultures, where some major spectral differences
are highlighted. (c) The two 2D 1H-13C HSQC spectra from (a-b) were added to yield a master spectrum that contains all the observed NMR
peaks. (d-f) Illustration of the procedure to generate a “difference spectrum” to facilitate metabolite identification by creating a signed (+, -,
null) peak list. (d-e) Representative 2D 1H-13C HSQC spectra obtained from two distinct bacterial cultures. (f) The two 2D 1H-13C HSQC
spectra from (d-e) were subtracted to yield a difference spectrum that identifies the NMR peaks, and correspondingly metabolites, that differ
between the two bacterial cell cultures. Positive peaks, increased metabolite concentration, are colored green and negative peaks, decreased
metabolite concentration, are colored red.
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discovery process by either identifying metabolic pathways
affected by a drug to evaluate efficacy or potential toxicity; or
by identifying potentially new therapeutic targets.
Nevertheless, accurate metabolite identification is very
difficult and labor-intensive. The success of metabolite
spectral assignment relies largely on the completeness of
metabolomics databases. We routinely use a combination of
the following freely-accessible databases: Human
Metabolome Database (http://www.hmdb.ca/) [88], Madison
Metabolomics
Consortium
Database
(http://
mmcd.nmrfam.wisc.edu/) [89], Platform for RIKEN
Metabolomics (PRIME) (http://prime.psc.riken.jp/) [90],
BioMagResBank (http://www.bmrb.wisc.edu/) [91], and
Metabominer
(http://wishart.biology.ualberta.ca/
metabominer/) [92], which provide both redundant and
complementary NMR spectral data. Importantly, the
reference NMR spectra in the various databases were
obtained under different buffer conditions and use different
internal standards. This results in a range of potential
chemical shifts for a given metabolite. Thus, the database
with sample conditions that closely match our experimental
conditions are used for chemical shift matching. The overall
goal is to identify a complete set of metabolites as quickly
and accurately as possible without any bias, by matching the
experimental chemical shifts from the 2D NMR spectra with
the values in the database.
For a 2D 1H-13C HSQC experiment, it is important to
realize that metabolites may be heterogeneously labeled by
the carbon-13 source present in the growth media.
Correspondingly, all the peaks for a specific metabolite may
not be detectable in the 2D 1H-13C HSQC experiment. Also,
a reference spectrum for the metabolite may not be present
in any of the available databases. The assignment of a
particular peak might still be ambiguous because multiple
metabolites may contain the same chemical shift or contain
an identical substructure (e.g., ATP, ADP, AMP or NAD,
NADPH). Therefore, a few automated filters are applied to
overcome some of these ambiguities during the peak
assignment process.
The first filter is to verify that the bacteria can actually
produce the proposed metabolite. This is routinely
accomplished by searching the freely-accessible Biocyc
(http://biocyc.org/) [94] and KEGG (http://www.genome.jp/
kegg/) [95] database for metabolites known to exist in the
bacteria under investigation. The second filter is based on a
differential peak list. All the NMR peaks potentially assigned
to a specific metabolite should have the same trend relative
to the control. Obviously, the metabolite can only have one
concentration and all the NMR peaks need to be consistent
with this single concentration. Correspondingly, all the
peaks have to be increased, decreased or the same relative to
the same peaks in the control spectrum. This is easily and
quickly visualized by subtracting the two sets of spectra and
generating a signed (+, -, null) peak list. Peaks assigned to
the same metabolite have to have the same sign. The third
filter is based on a biological relationship with other

metabolites. Simply, the likelihood of a correct assignment
increases if other metabolites in a specific metabolic pathway
have also been assigned. It is more likely to observe multiple
metabolites from the same pathway than various metabolites
from unrelated pathways. Similarly, if there is a direct
metabolic path between two or more metabolites, then their
assignments are more likely to be correct. The final filter is
the application of our biological knowledge of the bacterial
system under investigation. The pathways or metabolites
that are expected to be perturbed by the treatment would be
given precedent in the assignment process. As a simple
example, a comparison between wild-type and mutant
bacterial strains where aconitase has been inactivated would
reasonably be expected to lead to changes in metabolites
associate with the TCA cycle. Likewise, a comparison
between untreated and drug-treated cells would be expected
to lead to changes in metabolic pathways inhibited by the
drug.
5.3.3 Statistical analysis of the 2D 1H-13C HSQC data.
After assigning the 2D 1H-13C HSQC spectra to a set of
metabolites, the next goal is to determine metabolite
concentration differences between the various bacterial
culture conditions under investigation. Unfortunately, peak
intensities in a standard 2D 1H-13C HSQC experiment are
dependent on multiple parameters [77, 78], so only a relative
percent change in a metabolite concentration can be
determined [5]. Alternatively, an absolute concentration can
be determined using HSQC0, which requires a set of three
HSQC experiments per sample. We routinely employ both
approaches [77].
A relative difference in peak intensities is determined by
using a triplicate set of a conventional 2D 1H-13C HSQC
experiment for each bacterial culture condition. Prior to
calculating a relative percent change in peak intensities, a
detailed normalization process is required, which was
previously described in detail [5]. First, the peak intensities
within each spectrum are normalized by dividing each peak
by the internal standard, the intensity of the TMSP-d4 peak.
Each peak pertaining to a specific chemical shift across each
triplicate data set is then normalized by the most intense
peak in the set of three peaks. Specifically, the maximal
intensity for each peak across all data sets would be set to
100 and all other intensities are scaled relative to this peak
intensity. Then all the normalized intensities for a given
metabolite for each triplicate set are averaged together, and a
relative percent error can be calculated between different
cultures. A Student’s t-test or ANOVA is then used to
determine if the relative change in peak intensities is
statistically significant at the 95% confidence limit.
Calculating a relative difference in metabolite concentrations
can be beneficial to understanding broader changes to the
system, especially when a cluster of metabolites in a specific
pathway exhibit a similar trend in concentration changes
inferring an important role for the metabolic pathway.
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Nevertheless, this approach is rather cumbersome and does
not allow for a direct comparison between different
metabolites.
Alternatively, we routinely use the HSQC0 experiment to
determine absolute metabolite concentrations. The overall
protocol for the extrapolation of peak intensities to timezero and the determination of the associated concentration
has been previously described in detail [77, 78]. A distinct
advantage of this method is that a single calibration curve
can be made using multiple compounds with known
concentrations to correlate the time-zero peak intensity with
a concentration. Figure 7 illustrates such a calibration curve
using 5 different mixtures, each consisting of 9 different 13Clabeled metabolites ranging in concentrations from 5 to 300
μM. Also, the concentration for each metabolite was
randomized in each mixture. For example the concentration
of 13C-D-alanine in the 5 mixtures is 300, 10, 25, 5, and 100
μM, respectively. The data was fitted using a weighted linear
least squares calculation. Notably, the best-fit line (R2 0.997)
has a y-intercept close to zero as expected for a
concentration of zero. Also, the correlation between peak
volume and concentration is independent of the metabolite.
Importantly, the accurate application of the calibration curve
requires collecting and processing HSQC0 spectra identical
to the parameters used to obtain the original calibration
curve. Critically, the receiver gain must be the same for all
samples, because any change in the receiver gain influences
the slope of the calibration curve. Also, the addition of 500
μM TMSP-d4 as an internal standard is crucial, because both
the calibration samples and experimental samples must both
be normalized to the TMSP-d4 peak. As an example, if the

TMSP-d4 peak volumes for the calibration mixtures are
1000, 500, and 250 for each HSQCi (i = 1, 2, 3) spectrum,
respectively, then the experimental results for all in vivo metabolite extracts must be normalized so that the internal
standard (TMSP-d4) peak volumes are also 1000, 500, and
250. The concentrations are measured in triplicate, where a
Student’s t-test or ANOVA is used to determine if the concentration changes are statistically significant at the 95%
confidence limit.
5.4 Metabolomics Network Map
Metabolites are highly interconnected through numerous
metabolic pathways that form an extremely complex network [96]. Correspondingly, it is not uncommon to observe
correlated changes between distantly connected metabolites.
In effect, metabolomics depends on these complex
interactions to understand the phenotype of a bacterial cell.
Thus, a metabolomics network map provides an efficient
approach to visualize and summarize the overall changes to
the metabolome, to validate metabolite assignments based
on clear connections to other metabolites, and the
identification of key metabolic pathways.
We
have
routinely
used
Cytoscape
(http://
www.cytoscape.org/) to easily and quickly generate
metabolomics network maps [97-100]. Cytoscape is a free,
user-friendly software package with plug-ins related to
metabolomics. Cytoscape simply requires a list of the
metabolites and their associated concentration changes as
input. The connections between nodes (metabolites) in the
map are based on metabolic pathways from the freely-

Figure 7. A strong correlation between NMR peak volumes and metabolite concentrations (R 2 0.997) is demonstrated by linear regression
plot generated from HSQC0 data. HSQC0 NMR spectra were collected for five different metabolite mixtures containing nine 13C-labeled compounds with concentrations ranging from 5 μM to 300 μM. The relationship between peak volume and metabolite concentration is independent of the metabolite.
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accessible MetaCyc database (http://metacyc.org/) [101]. An
example of a typical Cytoscape map summarizing the
observed changes in the S. epidermidis metabolome caused
by environmental stimuli associated with biofilm formation
is shown in Figure 1. The metabolomics network map can be
easily modified to highlight specific features of the
metabolome. Edges can be broadened to highlight specific
pathways; and the color and size of nodes can be adjusted to
reflect the direction and magnitude of the concentration
changes, respectively [102]. Cytoscape also provides a range
of map design choices. Unfortunately, the resulting network
maps (Figure 1) do not resemble standard metabolic
pathways. Thus, Cytoscape maps are simply used as a
template to manually draw more traditional looking
metabolic pathways. Since Cytoscape maps are so easily
generated, we also use the software to assist in metabolite
assignments. Potential lists of metabolite assignments are
input into Cytoscape to identify metabolites that are isolated
nodes excluded from the main network map. These
metabolites are likely misassigned and are reevaluated. In
addition to Cytoscape, we also use the free R statistics
package (http://www.r-project.org/) [103] to create heat
maps from absolute metabolite concentrations or percent
relative concentration changes.
6. Conclusion
NMR metabolomics is an invaluable tool for systems biology and its application is rapidly expanding. Global changes
in the metabolic state of bacterial cells occur as a result of
environmental stressors, genetic modifications, drug treatments, or numerous other factors. A detailed analysis of the
differences in the NMR spectra is commonly used to identify
the key metabolite changes that differentiate between these
bacterial classes (e.g., controls versus treated). In addition,
metabolite identification by NMR allows for the subsequent
identification of the important metabolic pathways that are
affected by the treatment, providing further insight into the
underlying biological process. The appeal of NMR metabolomics is its simplicity, but unfortunately it is also easy to
obtain unreliable results. The observed changes in the
metabolome should be biologically relevant, but because the
metabolome is so sensitive to any environmental change; it is
also easily perturbed by the experimental protocol. This is
clearly an undesirable outcome. To address this issue, we
described in detail our optimized protocols for the NMR
analysis of bacterial metabolomes. We also highlighted common problems and potential sources of mistakes. We discussed the entire process that includes growing and harvesting bacterial cells, extracting the metabolome, NMR data
collection, processing and analysis, statistical analysis, metabolite and network identification. The protocols described
have been successfully applied to a number of systems biology projects [5, 49, 50, 52, 104-106].
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